Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash. [electronic resource]
Producer: 20130605Description: 747-52 p. digitalISSN:- 1423-0240
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Comorbidity
- Dose-Response Relationship, Drug
- Drug Eruptions -- epidemiology
- Erlotinib Hydrochloride
- Female
- Humans
- Japan -- epidemiology
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Prevalence
- Prognosis
- Protein Kinase Inhibitors -- therapeutic use
- Quinazolines -- therapeutic use
- Risk Assessment
- Risk Factors
- Survival Analysis
- Survival Rate
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.